John Frederick de Groot MDProfessor and Chairman ad interim, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. John de Groot is Professor and Chairman ad interim in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He provides exceptional care to patients in the Brain and Spine Center. Dr. de Groot directs both clinical and translational programs in the fields of glioma angiogenesis and molecularly targeted therapy, which have led to unique therapeutic approaches for the treatment of glioblastoma. Dr. de Groot has served as the principal investigator or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the PI of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a leader of MD Anderson’s Glioblastoma Moon Shot. As director of the Neuro-Oncology Fellowship Program, he is also helping develop the next generation of neuro-oncologists.
Dr. de Groot was awarded his medical degree by The University of Texas Medical Branch at Galveston. He received residency training in neurology at Johns Hopkins School of Medicine in Baltimore, and completed his clinical fellowship in Neuro-Oncology at The University of Texas MD Anderson Cancer Center in Houston.
Dr. de Groot has published 80 peer-reviewed articles. He is or has been a peer reviewer for 23 national and international scientific journals and serves on four editorial review boards.
Grant or Research Support: Sanofi-Aventis, Astrazeneca, EMD-Serono; Eli Lilly, Novartis, Deciphera Pharmaceuticals, Mundipharma.
Paid Consultant: Celldex; Deciphera Pharmaceuticals, AbbVie, FivePrime Therapeutics, Inc., GW Pharma, Carthera, Eli Lilly, Kadmon, Boston Biomedical Inc.,Taiho Pharmaceuticals, Kairos Venture Investments, Syneos Health, Monteris, Agios, Mundipharma Research, GenomiCare, Blue Earth Diagnostics, Del Mar Pharmaceuticals, Insightec, E-Health Now, Voyager Therapeutics, Inc.
Advisory Boards: Genentech, Celldex, Foundation Medicine, Inc., Novogen, Deciphera, Astrazeneca, Insys Therapeutics, Merck, Eli Lilly, Novella Clinical, Karyopharm Therapeutics, Blue Earth Diagnostics, Kiyatec, Vanquish Oncology, Orsenix, Insightec, Prelude Therapeutics, Debiopharm Therapeutics, Inc.
Other Relevant Financial or Material Interests: DSMB: VBL Therapeutics [Glioblastoma (VB111)]; DSMB: Novella [Glioblastoma (ICT-107)]; VBI Vaccines, Inc [Glioblastoma (VBI-1901)].
Stock Ownership: Ziopharm Oncology, Gilead
Company Employment (Spouse): Ziopharm Oncology
Recent Contributions to PracticeUpdate:
- Management of Glioblastoma in the Elderly
- Challenges and Strategies for Developing Checkpoint Inhibitors in Glioblastoma
- VAL-083 for Patients With MGMT-Unmethylated Glioblastoma
- Future Directions for GBM: A Multidisciplinary Review
- Hypermutator Phenotypes and Genomic Analyses of Gliomas: Updates From SNO 2017
- New Data and Current Concepts in High Risk Meningioma From SNO 2017
- Key Strategies for Treating Elderly Patients With Glioblastoma
- Biomarkers and Targeted Therapies for Glioblastoma
- Clinical Implications of New Data from SNO 2016 on the Treatment of Low Grade Gliomas
- ACT IV Study Failure: Implications for Vaccine Therapy in High Grade Glioma From SNO 2016